2,475 results on '"Oldenburg, J."'
Search Results
2. Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU
3. Bleeding phenotype according to factor level in 825 children with non-severe hemophilia; data from the PedNet cohort
4. First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts
5. Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer.
6. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
7. Patient-reported pain in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from a phase 3 (TALAPRO-2) study
8. PB0624 A-SURE: Intra-Patient Comparison of Prophylactic Effectiveness of a Recombinant Factor VIII Fc Fusion Protein Versus Standard Half-Life Factor VIII in Hemophilia A
9. PB1249 Prospective, Observational Study of the Clinical Characteristics of Adults and Adolescents with Severe Hemophilia A
10. PB1073 Endothelial Cell-Dependent Activated Protein C Formation is Significantly Decreased in Hereditary Protein C Deficiency Regardless of Underlying Gene Variant and Residual Activity in Plasma
11. PB1263 Third Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol in Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World HEM-POWR Study
12. PB0830 Inspecting Underlying Pathogenesis Mechanisms of Von Willebrand Disease Variants Sited in A Domains of the von Willebrand Factor
13. OC 07.2 Investigating the Dominant Negative Effect of Heterozygous F13B Gene Mutations Detected from Mild FXIII Deficiency Patients
14. PB1075 APC Response Rates in Factor V Leiden Carriers Correlate with Thrombotic Risk Independent from Endothelial Properties: Results from an Endothelial Cell-Based ex vivo Model of the Protein C Pathway
15. PB0151 The Effect of Single and Combined Knockouts of GABARAPs Proteins Family on FVIII Intracellular Localization and Secretion
16. PB1292 Rationale and Design of PathfinderReal: A Prospective, Non- Interventional Study Assessing Joint Health in Adults With Haemophilia A after Switching to Prophylaxis with Turoctocog Alpha Pegol (N8-GP)
17. OC 20.1 Bleeding, FVIII Activity, and Safety 3 Years After Gene Transfer with Valoctocogene roxaparvovec: Results from GENEr8-1
18. OC 33.5 Structural Characterization of Coagulation Factor VIII
19. OC 04.2 B-domain Deleted Factor VIII Shows Clear Differences in Intracellular Processing and Cellular Responses when Compared to Full Length Factor VIII
20. PB1255 An Update on Real-World use of rVIII-SingleChain in Patients with Haemophilia A in Germany: Interim Results from a Prospective, Non- Interventional Study
21. OC 04.3 Prospective FVIII Intracellular Trafficking Routes Involving GABARAP
22. PB1296 A Prospective, Non-Interventional Study to Investigate the Effectiveness of rVIII-SingleChain in Patients with Hemophilia A
23. PO10 Nuwiq Dosing and Outcomes in the Management of Women/Girls with Haemophilia A Needing FVIII Treatment for Surgery - An International, Open-Label, Non-Controlled Study (NuDIMENSION)
24. PB0681 German Experience with Simoctocog alfa during Surgery in Female Haemophilia A Carriers
25. OC 33.3 Evaluating the Impact of anti-PEG Antibodies on Activation of PEGylated Therapeutic FVIII Products
26. PB1198 Retrospective Genotypic Data Analysis of Patients with Suspected Hereditary Fibrinogen Deficiency
27. OC 43.4 Effectiveness of Emicizumab Under Real-World Conditions in Patients of All Ages with Hemophilia a with and Without FVIII Inhibitors: Interim Analysis of the Non-Interventional Study EMIIL
28. PB0158 Preanalytical Quenching of FVIII Using FVIII-Inhibitors Improves the Specificity of Functional Emicizumab Testing
29. LB 01.2 Emicizumab Prophylaxis Instead of Immunosuppressive Therapy in Patients with Acquired Hemophilia A (AHA)
30. PB0143 Induced B Cell Tolerance in Hemophilia A Mice is Destroyed by Infections
31. PO19 Clinical Experiences in Managing the Transition to rIX-FP: Switching, Surgical Management and On-Demand
32. PB1502 Hemostatic Imbalance Associated with Tamoxifen in Estrogen Receptor-Positive Breast Cancer Patients: An Observational Study
33. Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII
34. In silico and in vitro evaluation of the impact of mutations in non-severe haemophilia A patients on assay discrepancies
35. Fibrinogen Bonn (p. Arg510Cys) in the Aα-Chain Is Associated with High Risk of Venous Thrombosis
36. What Are the Long-Term Toxicities to Be Controlled and Treated?
37. Prävalenz von Osteoporose bei Patienten mit Hämophilie in Abhängigkeit der Schwere der Gerinnungserkrankung
38. A systematic review of the efficacy and toxicity of brachytherapy boost combined with external beam radiotherapy for nonmetastatic prostate cancer
39. Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA)
40. Identification and functional characterization of a novel F5 mutation (Ala512Val, FVBonn) associated with activated protein C resistance
41. A critical appraisal of one‐stage and chromogenic assays of factor VIII activity
42. Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU
43. Transcriptome-wide analysis of filarial extract-primed human monocytes reveal changes in LPS-induced PTX3 expression levels
44. Pain in patients with hereditary bleeding disorders: evaluation of a survey among people affected in Germany
45. Elevated plasminogen activator inhibitor-1 is not associated with impaired plasmin formation and thrombotic risk after low-grade coagulation activation in vivo
46. Low resolution cryo-EM maps and AFM analysis combined with alpha fold model of full-length coagulation Factor VIII sheds light on the conformational positioning of the Factor VIII B domain
47. An improved understanding of native coagulation factor XIII complex structure using cryo-EM
48. Establishment and specification analysis of LSEC-like endothelial cells for the detection of endogenous FVIII
49. Updated interim safety analysis of the real-world HEM-POWR study evaluating damoctocog alfa pegol in previously treated patients with haemophilia A
50. In-vitro and In-silico characterization of a pathogenic variant in integrin β3 associated with hereditary macrothrombocytopenia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.